HTLV-1 proviral research for the control of ATL

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461428
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Hematology
• Research Institution: Kumamoto University
• Principal Investigator: SATOU YORIFUMI 熊本大学, 大学院先導機構, 准教授 (70402807)
• Research Collaborator: MIYAZATO Paola 熊本大学, 大学院先導機構, 博士研究員 ; UTSUNOMIYA Atae 今村病院分院, 血液内科, 医師 ; KATSUYA Hiroo 熊本大学, エイズ学研究センター, 博士研究員 ; MATSUO Misaki 熊本大学, 医学生命科学研究科, 大学院生 ; TOKUNAGA Michiyo 熊本大学, エイズ学研究センター, 技術補佐員
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: ウイルス / 白血病 / HTLV-1 / エピジェネディスクス

Outline of Final Research Achievements

I have analyzed epigenetic features of HTLV-1 provirus in ATL cell lines and PBMCs of ATL patients, and then identified a DNA-binding protein CTCF directly binds to HTLV-1 provirus (Satou et al, 2016). CTCF is known as a key molecule for epigenetic regulation of human genome. Our result suggests that CTCF should also play a role in regulation of HTLV-1 proviral transcription. In terms of integration site analysis, we have collected longitudinal clinical samples of ATL patients and HTLV-1 asymptomatic carriers. I am going to continue and extend this research.

Free Research Field

血液内科学